Developing a bedside blood analyzer to monitor antibiotic levels
Vancomycin dosing must balance infection control against kidney toxicity. In serious MRSA infections, clinicians need to reach effective drug exposure early, while monitoring treatment to avoid excessive exposure and harm. This makes timely drug-level information important for dose adjustment.
Aptamedica is developing AptaSense, a point-of-care blood analyzer for therapeutic drug monitoring. It uses aptamer sensors to detect drug molecules in venous blood, with initial assays focused on vancomycin monitoring and IL-6 detection.
What stands out about Aptamedica
Co-founder Kamil Pawełkiewicz is a medical doctor and Jagiellonian University Medical College graduate with emergency medicine experience.
Co-founder Mateusz Fil is a biophysicist and Jagiellonian University PhD candidate specializing in biosensors and electrochemical diagnostics.
Reports completing paid contract R&D on an electrochemical insulin biosensor proof of concept for an undisclosed customer.
Reports developing its first AptaSense prototype and conducting initial internal proof-of-concept testing in 2024.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.